These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6797388)

  • 1. Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
    Lavin PJ; Gawel MJ; Das PK; Alaghband-Zadeh J; Rose FC
    Arch Neurol; 1981 Dec; 38(12):759-60. PubMed ID: 6797388
    [No Abstract]   [Full Text] [Related]  

  • 2. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
    Lawton NF; MacDermot J
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1012-5. PubMed ID: 6777462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberoinfundibular dopaminergic function in Parkinson's disease.
    Franceschi M; Camerlingo M; Perego L; Bottacchi E; Truci G; Mamoli A
    Eur Neurol; 1988; 28(3):117-9. PubMed ID: 3133213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
    Vogel HP; Ketsche R
    J Neurol; 1986 Jun; 233(3):149-52. PubMed ID: 3088217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
    Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
    Rappelli A; Glorioso N; Tedde R; Dessi'-Fulgheri P; Monaco F
    J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):915-8. PubMed ID: 731241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
    Carlson HE
    J Clin Endocrinol Metab; 1986 Jul; 63(1):249-51. PubMed ID: 3086358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 14. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
    Barbeau A
    Can Med Assoc J; 1975 Jun; 112(12):1379-80. PubMed ID: 1139474
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of L-DOPA on the hypothalamic-pituitary-thyroid axis.
    Burrow GN; Spaulding SW; Donabedian R; Van Woert M; Ambani L
    Adv Neurol; 1974; 5():489-93. PubMed ID: 4216258
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sinemet and thyroid function in Parkinson disease.
    Wingert TD; Hershman JM
    Neurology; 1979 Jul; 29(7):1073-4. PubMed ID: 572939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
    Yahr MD; Clough CG; Bergmann KJ
    Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.